Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 29, 2015 3:30 AM ET


Company Overview of CSL Behring LLC

Company Overview

CSL Behring LLC, a biopharmaceutical company, engages in the research, development, manufacture, and marketing of protein-based therapies for the treatment of serious and rare conditions worldwide. It offers bleeding disorder, fluid replacement, hereditary angioedema, immunoglobulin, pulmonary, and wound healing biotherapies. The company also operates a plasma collection network. Its therapies are indicated for the treatment of coagulation disorders, including hemophilia and von Willebrand disease; primary immune deficiencies; neurological conditions; inherited respiratory diseases; hereditary angioedema; and cardiac surgery, organ transplantation, burn treatment, and hemolytic disease preve...

1020 First Avenue

P.O. Box 61501

King of Prussia, PA 19406-0901

United States

Founded in 2000





Key Executives for CSL Behring LLC

Chief Executive Officer and Managing Director
Age: 58
Chief Financial Officer and Senior Vice President of Research & Development
Age: 52
Executive Vice President of Global Commercial Operations
Age: 56
Chief Scientific Officer and R&D Director
Age: 60
Executive Vice President of Legal and General Counsel
Age: 54
Compensation as of Fiscal Year 2015.

CSL Behring LLC Key Developments

CSL Behring Approves Health Canada for the Treatment of Hereditary Angioedema

CSL Behring announced that Health Canada has approved a new, low-volume presentation size for the existing indications of Berinert®, a human plasma-derived, pasteurized and nanofiltered C1-esterase inhibitor (C1-INH) concentrate. The new Berinert® 1500 IU format is reconstituted with 3 mL vial of Sterile Water for Injection (Diluent). In Canada, Berinert® is indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) of moderate to severe intensity. Berinert®, licensed since 2010, is the first C1-INH available in Canada. The new vial size with 1500 International Units of C1-esterase inhibitor can be prepared and administered faster than the same dose using the existing vial size of 500 IU. This is particularly significant for patients who weigh more than 50 kilograms. In the past, these patients had to mix three different vials of C1-esterase inhibitor before administration. This new concentrated formulation allows patients over 50 kilograms to mix and administer just one vial.

U.S. FDA Accepts for Review CSL Behring's Biologics License Application for rIX-FP for Hemophilia B Patients

CSL Behring announced that the U.S. Food and Drug Administration has accepted for review its Biologics License Application (BLA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). Upon FDA approval, rIX-FP will provide hemophilia B patients with a long-acting treatment option with dosing intervals up to 14 days. FDA's decision to accept for review the rIX-FP BLA brings CSL Behring one step closer to providing this innovative therapy to hemophilia B patients in the U.S. The development of rIX-FP underscores CSL Behring's protein science capabilities, thorough understanding of the hemophilia community, and commitment to improving the well-being of patients with hemophilia B.

CSL Behring Submits Biologics License Application for FDA Approval

CSL Behring announced that it has submitted a biologics license application (BLA) to the United States Food and Drug Administration (FDA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). Once approved by the FDA, rIX-FP (Coagulation Factor IX {Recombinant}, Albumin Fusion Protein) will provide people with hemophilia B and their physicians a long-acting treatment option with dosing intervals up to 14 days.

Similar Private Companies By Industry

Company Name Region
CELLSCRIPT, Inc. United States
Nanodisc, Inc. United States
Cencor Biotech Inc. United States
Evogene, Inc. United States
Leptogen, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CSL Behring LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at